Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Clinical trial NCT07581834 · RECRUITING

Trial details

NCT number: NCT07581834
Sponsor: Fujian Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Diseases Breast Neoplasms Dalpiciclib Endocrine Breast Diseases CDK4/6 Inhibitor HR+/HER2- Breast Cancer

Start date: 2026-01-21
Primary completion: 2031-12-31
Enrollment: 2000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.